Descovy® (emtricitabine/tenofovir alafenamide) – New indication
October 3, 2019 - The FDA announced the approval of Gilead’s Descovy (emtricitabine/tenofovir alafenamide), in at-risk adults and adolescents weighing at least 35 kg for pre-exposure prophylaxis (PrEP) to reduce the risk of human immunodeficiency virus-1 (HIV-1) infection from sexual acquisition, excluding individuals at risk from receptive vaginal sex.
Top